Integrating Bioelectronic Signals with MedicalImaging and AI for Real-Time Monitoring of Brain Tumor Recurrence: A perspective

Laiba Hamid[1] and Imran Riaz[2]

[1]Department of Computer Systems Engineering, Mirpur University of Science and Technology, Mirpur Azad Kashmir, Pakistan

[2]Department of Biomedical Engineering Technology, MIT, Mirpur University of Science and Technology, MUST Mirpur Azad Kashmir, Pakistan

Corresponding Author:

Imran Riaz

Department of Biomedical Engineering Technology, MIT, Mirpur University of Science and Technology, MUST Mirpur Azad Kashmir, Pakistan

Allama Iqbal Road, Mirpur, Azad Jammu Kashmir (AJK), Pakistan

Email: imran.ee@must.edu.pk

Phone: +92-344-5591533

Word Count: 3859 words

Number of Figures: 6

Number of Tables: 5

Abstract

The recurrence of brain tumors continues to pose a significant clinical obstacle, with numerous survivors encountering elevated risks of relapse even following surgical resection, radiotherapy, and chemotherapy. Present monitoring approaches primarily depend on periodic neuroimaging, which faces limitations related to cost, accessibility, and its inability to detect subtle neurophysiological alterations between scans. Recent developments in flexible, stretchable bioelectronic devices particularly the neural implants generated through the embryonic integration of ultrathin, biocompatible electronics represent a transformative approach for achieving continuous brain monitoring. Unlike traditional rigid electrodes or standard brain-machine interface (BMI) systems, these devices demonstrate long-term stability, adaptability to brain tissue, and a minimal immune response, making them viable candidates for chronic implantation in tumor survivors. In this review, we advocate for a future model in which such bioelectronic devices are integrated with artificial intelligence (AI)-enhanced medical imaging systems to establish a continuous diagnostic ecosystem. Implantable sensors could gather electrophysiological and biochemical data that, when combined with deep learning based radiomics and radiogenomic frameworks, would facilitate real-time identification of early biomarkers indicative of tumor recurrence. By linking bioelectronic signal streams with longitudinal imaging information, AI systems could reveal recurrence patterns that are not perceptible to human analysis, thus providing predictive alerts and tailored intervention strategies. We also examine potential clinical workflows, data integration frameworks, and the challenges associated with biocompatibility, multimodal data fusion, and obtaining regulatory approval. Ultimately, we delineate a pathway toward neuroadaptive, AI-enhanced monitoring platforms that can extend beyond oncology to encompass other neurological disorders. This integration of soft bioelectronics with AI-driven neuroimaging holds the promise to revolutionize post-treatment care, transitioning recurrence detection from being episodic and reactive to being continuous and proactive, thereby enhancing survival rates and improving the quality of life for patients with brain tumors.

Keywords: Brain-machine interface, bioelectronics, medical imaging AI, brain tumor recurrence, continuous diagnostics, neuro-oncology, cancer.

1. Introduction

Brain tumors continue to rank among the deadliest types of cancer throughout the world, with high morbidity, mortality, and recurrence especially in Asia. In 2022 more than 300,000 new cases of Brain tumors and other central nervous system tumors were reported by WHO, with an estimated 250,000 worldwide annual death [6]. Figure 1 shows the area specific graphical representation of statistics of Brain and CNS tumors.






Figure 1: Area-specific distribution of brain and CNS tumor incidence across different regions.


Despite improvements in surgical intervention, chemotherapy, and radiation, glioblastoma multiforme (GBM); the most frequent malignant brain tumor only averages a 12–15 month survival and near universal recurrence [6], [7]. Furthermore, approximately 90% of GBM patients experience tumor recurrence following initial treatment [20]. Even in low-grade gliomas (LGGs), which are generally slower growing and more benign, recurrence remains a significant concern: one study found that 28% of patients with resected LGGs experienced recurrence within two years, and 72% by two years [20]. This high rate of recurrence across glioma grades underscores the urgent need for innovative continuous monitoring technologies.



(a) Low-Grade Gliomas Recurrence Rate



(b) Combined Glioma Grades Recurrence



(c) Glioblastoma Recurrence Rate

Figure 2: Pie chart visualization of recurrence rates for different brain tumors. (a) Low-grade gliomas (28-44% recurrence), (b) Combined Glioma (80% recurrence), (c) Glioblastoma multiforme (90% recurrence) [20].

1.1 Challenges for Tracking Brain Tumor Reappearance

Routine clinical practice employs intermittent magnetic resonance imaging (MRI) scans for follow-up of tumor survivors. Nevertheless, surveillance based on MRI is infrequent, expensive, and usually misses early microscopic changes preceding macroscopic recurrence [10]. Also, it is difficult to differentiate true tumor recurrence from late treatment side effects like radiation necrosis [10]. EEG has been investigated as a supplementary technique, as gliomas recurs often produce characteristic electrophysiological perturbations [8], [9]. Nonetheless, surface EEG by itself is deficient in spatial resolution and sensitivity for successful, long-term follow-up.

1.2 The Development of Long-Term Cerebral Monitoring Using Soft Bioelectronics

Recent advances in bioelectronic systems open new possibilities for the ongoing and minimally invasive evaluation of neural function. The seminal report by Liu *et al.* described the implantation of thin, soft, and stretchable bioelectronics in the brain in embryonic life, with subsequent seamless integration with neural tissue and excellent long-term stability [1]. Such ultraflexible devices overcome the shortcomings of traditional rigid electrodes by reducing immune responses and providing for chronic operability. At the same time, flexible and microchannel-based bioelectronic implntation studies highlight the expanding possibilities for the repeated acquisition of neurophysiological information in a clinical environment [12], [14].

1.3 Medical Imaging and Diagnosis of Tumor Reoccurrence with Artificial Intelligence

Computer vision, and more specifically AI, has revolutionized analysis of medical imaging. Convolutional neural networks (CNNs) and sophisticated architectures like ResNets [5] and nnU-Net [11] have yielded state-of-the-art performance for segmentation and classification problems in neuro-oncology. The transformer-based models have further boosted the potential to handle global dependencies in brain tumor MRI [13]. Notably, AI has also demonstrated potential in differentiating recurrence from radiation necrosis and other treatment changes, enhancing diagnostic precision beyond human-based analysis [4], [10]. Additionally, multimodal fusion approaches of imaging with genomic and clinical information are being investigated to boost predictive precision [15].

1.4 Convergence of Bioelectronics and AI for Ongoing Diagnostics

We picture the development of a future diagnostic system in which soft bioelectronic implants repeatedly gather electrophysiological and biochemical signals from the

brain and transfer such data to AI-enhanced imaging platforms. By integrating iterated neural recordings with radiomic and radiogenomic analysis, AI systems may detect subtle recurrence biomarkers long before conventional imaging reaches determination results. The proposed system would facilitate real-time warning, individually tailored intervention plans, and ultimately trigger a shift from reactive to proactive survivorship of brain tumor survivors. The concept is an extension of decades of work on brain–machine interfaces (BMIs) [2], [3], applying them from motor restoration to cancer surveillance.

1.5 Ethical, Technical, and Clinical Considerations

While the promise of the merger of bioelectronics and AI is immense, there are issues to address. Some of these are long-term safety and biocompatibility of the implant, production of scalable AI models transferring well from diversified patient pools, and privacy-enhancing protocols such as the federated learning [19] for safeguarding patient information. There also has to be guidance from ethical frameworks for using such intrusive monitoring systems, namely problems of autonomy, consent, and equity of access [16], [17].

1.6 Scope of This Investigation

This paper investigates the emerging combination of soft bioelectronic implants and AI-enhanced neuroimaging for real-time quantification of brain tumor recurrence. Section II canvasses developments in bioelectronic neural interfaces. Section III contrasts deep learning approaches to brain tumor imaging. Section IV investigates possible frameworks for multimodal fusion of imaging data and multimodal bioelectronic signals. Section V identifies ethical and translational issues, and Section VI provides a strategic roadmap for deployment. By uniting these fields, we outline a direction toward future-generation continuous diagnostic platforms that have the potential to revolutionize the management of neuro-oncology.

Proposed Taxonomy of Brain Tumor Recurrence Monitoring Approaches

Existing literature on brain tumor recurrence monitoring can be systematically categorized into three complementary domains:

- **Bioelectronic Signal Acquisition** – shape-changing and adjustable wearables and implants that offer electrophysiological and biochemical signals at high temporal resolution [1, 12, 24, 25].
- **AI-Enhanced Imaging** – deep learning pipelines (CNNs, transformers, radiomics/radiogenomics applied on structural and functional imaging for recurrence detection [4, 5, 10, 11, 13, 29, 30].

- **Multimodal Fusion and Clinical Decision Support** – systems that combine bioelectronic and imaging data in order to produce readable, real-time alerts and therapeutic recommendations [15, 19].




Figure 3: Recommended taxonomy of brain tumor recurrence surveillance with the coordinated operations of bioelectronics, AI-based imaging, and multimodal clinical decision support.

2. Background and Motivation

2.1 Brain Tumor Recurrence in Neuro-Oncology

Gliomas and other malignant tumors of the brain demonstrate high recurrence rates even after aggressive treatment. Continuous diagnostic surveillance could significantly improve outcomes by enabling early detection of tumor regrowth [6], [7]. Current imaging intervals leave critical temporal gaps in monitoring.

2.2 Brain–Machine Interfaces and Bioelectronics

BMIs allow bidirectional communication with neural circuits. The integration of soft, flexible bioelectronics as shown in [1] provides a long-term solution to signal acquisition with minimal immune rejection. This technology enables continuous collection of electrophysiological markers such as electroencephalography (EEG) and local field potentials, which may change with tumor recurrence [8], [9].

2.3 Early detection of recurrence for brain tumors

Conventionally, brain tumor recurrence surveillance was dependent on a battery of periodic structural imaging, clinical assessment, electrophysiological testing, and periodic invasive biopsies. The most common clinical imaging technique has been magnetic

resonance imaging (MRI) due to its superb soft-tissue contrast and multiparametric sequences (T1/T2/FLAIR, contrast-enhanced imaging, perfusion imaging), which optimize perception of residual or recurrent disease [11, 4]. Computed tomography (CT) became an earlier and more convenient imaging modality; however, it lacks the soft-tissue sensitivity and contrast definition of MRI and thereby its utility for demonstrating subtle recurrence [11] and [4].

Surveillance by radiology, nonetheless, is marked by various well-established shortcomings. Imaging is periodic, most often at week-to-month intervals, and results in temporal blind intervals wherein microscopic recurrence advances undetected. Also, changes induced by treatment, like pseudoprogression and radiation necrosis, often produce imaging features indistinguishable from true tumor regrowth and complicate clinical decision-making and sometimes prompt invasive stereotactic biopsy for conclusive clarification [21, 22]. The promise of electrophysiological monitoring, and in particular, of surface EEG, has been explored as an adjunctal device, considering that cortical irritation and epileptiform changes due to tumors have been recognizable on EEG; however, traditional surface EEG is compromised by its spatially nonselective and depth-insensitive nature and provides only indirect information on tumor biology [8, 9]. Therefore, initial approaches have emphasized rigorous imaging interpretation, live monitoring, and histopathological correlation approaches that are effective but have shortcomings in early recognition and attendant hazards of procedures.

2.4 Identifying brain tumor recurrence using AI

In the past decade, artificial intelligence (AI), specifically deep learning (DL), has revolutionized medical image analysis and provided novel solutions for the recurrence challenge. Deep convolutional neural networks (CNNs) and current successors thereof automatically segment tumors, measure volumetric change, and acquire imaging features of recurrence predictivity that commonly elude human observers [4, 11]. Radiomics quantitative feature extraction from conventional imaging in high-dimensional spaces and its combination with machine learning has yielded recurrence risk prognostic signs and temporal models of tumor evolution [4].

DL-based pipelines (segmentation + feature extraction + classification/regression) have been applied to such tasks as separation of true progression from treatment effects, prediction of time-to-recurrence, and assistance with longitudinal response evaluation [10, 11]. Such systems have several benefits: automatic reproducibility, enhanced sensitivity to subtle shape/textural detail, and the potential of aggregating multimodal imaging (perfusion MRI, diffusion, PET) for more-complete decision-making [4, 10]. Serious limitations remain, however. Strong performance necessitates large, varied, and well-annotated sets; most publicly accessible brain tumor sets have bias toward particular

scanners, protocols, or patient groups and do not generalize well [4]. Interpretability is also a caveat: "black-box" models have the potential of evidencing suspicious regions without providing human-interpretable explanation, hindering acceptance by clinicians and approval by regulatory agencies. Finally, models constructed on DL act on intermittent imaging snapshots and thereby still do not provide continuous temporal resolution except to the extent of severally escalating imaging frequency an impracticable solution for most patients [4].

Table 1: Recent AI Methods for Brain Tumor Recurrence Detection

Ref	Year	Dataset	Task	Performance	Limitations
[11]	2021	BraTS	Tumor segmentation	Dice ∼0.90+	Requires large annotated datasets
[13]	2022	TCIA	Tumor classification	Acc. 89%	Limited generalizability across centers
[10]	2020	Local clinical MRI	Recurrence vs. necrosis	AUC 0.87	Small single-center dataset
[30]	2019	Multicenter MRI	Automated response assessment	Robust clinical validation	Interpretability challenges
[15]	2020	TCGA/ TCIA	Radiogenomics + recurrence prediction	High correlation with outcomes	Lack of multimodal datasets

2.5 Bioelectronics for brain tumor recurrence detection

Bioelectronic neural interfaces have appeared more recently as an adjunct means offering real-time electrophysiological and (in selected designs) neurochemical recording. Conventional intracranial electrodes (ECoG grids, depth electrodes) provided high-fidelity local signals previously used in epilepsy monitoring and neurosurgical mapping, but hard structures tend to cause chronic tissue response and signal degradation with time [12]. Material and device engineering advances have produced flexible, stretchable, and ultrathin devices that conform to brain tissue, ensure minimal mechanical mismatch, and allow for longer-term stable recording [1].

An important recent achievement showed a tissue-level soft mesh microelectrode array integrated into the growing brain by embryonic delivery and maintaining long-term integration with minimal immune response [1]. Though the study in Nature 2025 was carried out using developmental models, it lays down essential principles (such as ultrathin

substrates, mesh architecture, and tissue-conforming mechanics) that have immediate implications for the design of adult clinical monitoring chronic implants. Flexible and stretchable bioelectronics have the potential for real-time recording of continuous electrophysiological time series (local field potentials, high-frequency oscillations, and evoked potentials) and, by combination with electrochemical sensors, have the potential for the monitoring of metabolic markers (such as lactate and glutamate) of the peritumoral microenvironment [12, 1]. Combining real-time bioelectronic streams with AI-assisted imaging analysis can overcome episodic MRI's temporal limitations: electrophysiological or neurochemical deficits can serve as early sentinels, enticing faster imaging or focal molecular testing (i.e., CSF ctDNA) for confirmation [21, 22]. However, translation has challenges: adult scarred tissue's long-term biocompatibility, power and telemetry forimplanted systems, safety and infection risk, and clinically validatedbiomarkers that predict recurrence reliably and not other pathologies(e.g., seizures, infection, inflammation) [12, 1].

Table 2: Recent Bioelectronic Modalities for Brain Tumor Monitoring

Device Type	**Modality**	**Duration Tested**	**Strengths**	**Limitations**
Mesh electronics [1]	Intracranial electrophysiology	>6 months (animal models)	Long-term tissue integration	Not validated in adult humans
Flexible ECoG grids [12]	Electrophysiology	Weeks–months	High spatial fidelity	Biocompatibility challenges
Wearable EEG [28]	Surface electrophysiology	Continuous monitoring	Portable, noninvasive	Poor spatial resolution
Microchannel neuroprosthesis [14]	Preclinical neurosignal recording	Rat model (months)	Proof-of-concept integration	Limited to animal studies
Stretchable sensor platforms [25]	Multimodal electrophysiology	Prototype	Comfortable and conformal	No tumor-specific validation

As shown in Table 3, different modalities for the identification of brain tumor recurrence have distinctive merits but also represent significant constraints, and that necessitates the integration of bioelectronic sensors and AI-aided medical imaging.

Table 3: Comparison of Methods for Brain Tumor Recurrence Detection

Ref and Method	**Strengths**	**Limitations**
MRI (structural, perfusion) [10]	High spatial resolution; widely available	Episodic; difficulty differentiating recurrence vs necrosis
PET (Amino acid tracers) [26]	Functional and metabolic information	Expensive; limited availability
EEG [8], [9]	Non-invasive detects seizure activity	Poor spatial resolution; limited specificity
CSF liquid biopsy (ctDNA) [27]	Molecular-level information	Invasive lumbar puncture required; low sensitivity in some cases
Bioelectronic Implants [1], [12]	Continuous monitoring; high temporal resolution	Biocompatibility and surgical implantation risks
Wearable EEG devices [28]	Portable, non-invasive	Limited sensitivity compared to intracranial monitoring

3. Integration of Bioelectronic Sensors and AI

The integration of bioelectronic sensors with artificial intelligence (AI) entails a paradigm shift in the current management of brain tumor recurrence. Unlike classic follow-up methodologies based on isolated imaging, this framework facilitates immediate monitoring by integrating implanted neural sensors with artificial intelligence-based systems Signal analysis, medical imaging, and deep learning are discussed. The ensuing subsections detail the function of each constituent—biosensors, artificial intelligence, imaging technologies, and clinical decision-making support—within this overall tracking system.

To represent the inputs of each constituent in the proposed integrated framework, Table 4 describes the function of the bioelectronic sensor, AI Imaging modalities and deep learning for the real-time tracking of brain tumor recurrence.

3.1 Implanted Bioelectronic Sensors for Continuous Monitoring

Bioelectronic implants are a new era in the approach to Continuous monitoring of neural activity in patients who have had surgical correction. resections of brain tumours. Standard monitoring methods, including periodic imaging Electroencephalography (EEG) gives scattered information, and therefore, it gaps in the detection of tumor

recurrence [8, 9]. By contrast, soft, flexible, and stretchable bioelectronic implants provide continuous, high-fidelity recordings of electrophysiological signals directly from cerebral tissue [1, 12]. These bioelectronic sensors are designed to be integrated effortlessly with

Table 4: Proposed Framework: Contribution of Each Component in Continuous Brain Tumor Recurrence Monitoring

Component	**Role in the Framework**	**Contribution to Recurrence Detection**	**Outcome**
Implanted Bioelectronic Sensor	Continuously records neural/electrical activity (EEG, LFP) in the patient's brain after surgery	Enables real-time monitoring of abnormal patterns suggestive of tumor activity	Provides first-line, continuous surveillance
AI Signal Analysis	Processes raw biosensor signals using deep learning models	Detects anomalies correlated with tumor recurrence risk	Generates alerts when recurrence risk is high
Medical Imaging (MRI/Radiomics)	Performed only if AI raises a recurrence risk signal	Provides structural/functional confirmation of suspected recurrence	Reduces unnecessary MRI scans, lowers costs
Deep Learning Imaging Analysis	Automated analysis of MRI/radiomics features	Differentiates recurrence vs. treatment effects (e.g., necrosis) with high accuracy	Confirms final diagnosis of recurrence or not
Clinical Decision Support	Integrates multi-modal evidence (sensor + AI + MRI)	Guides timely intervention, follow-up, or therapy adjustment	Improves survival outcomes through early detection

neural tissue. while simultaneously reducing the likelihood of inflammatory reactions or signal deterioration. Their thin-film arrangements and biocompatible materials ensure that they are working Across longer timeframes, getting through a primary issue associated with strict implantable devices. systems [24, 25]. The capacity to identify small electrical Disturbances associated with alterations in the tumor microenvironment or dysrhythmic neural activity. make them especially useful in early recognition of recurrence.

Additionally, bioelectronic implants are now being developed with integrated inwireless power and Data transfer capability, in support of non-invasive interrogation and real-time data communicating data with peripheral devices [14]. These settings also increase patient Comfort and protection but also render continuous monitoring clinically feasible. For For instance, in animal research, implantable neural probes have successfully

tracked Biochemical and electrophysiological indexes within prolonged time intervals, confirming their translational potential [1].

These advances, overall, pave the way towards a next-generation monitoring system whereby bioelectronic implants are utilized as the primary data acquisition Nodes within a composite system for brain tumor recurrence detection.

3.2 AI Signal Analysis for Early Recurrence Prediction

The methods of artificial intelligence are central in research in the vast Streams of biosignal information produced by embedded sensors. EEG-centered recurrence Monitoring has been promising in revealing abnormal discharges as well as seizure patterns. associated with gliomas and with other intracranial neoplasms [8, 9]. Manual processing of such data is a time-wasteful and error-prone activity. AI-powered signal analysis overcomes the above challenge by utilizing machine learning algorithms to identify nuanced alterations in signals that could indicate impending observable tumor recurrence.

Deep neural networks and recurrent neural networks have been applied in neurosignal classification, with greater sensitivity and specificity than old statistical techniques [4, 5]. Specifically, feature extraction The utilization of convolutional neural networks (CNNs) has facilitated the automatic identification of signs in EEG or local field potentials otherwise undistinguishable To doctors [13]. These are important in the early detection of Recurrence, during which interventions are most effective.

Moreover, recent developments in federated learning make it possible to train simultaneously Models in various institutions without breaching confidentiality of patients [19]. This is especially critical in neuro-oncology, whose data are often small and heterogeneous. The intermingling of edge and federated systems of AI supports conditions-based, immediate analysis straight from data streams from sensors, thereby ensuring High-risk indicators elicit timely downstream imaging responses.

As the initial stage in the monitoring pipeline where decisions are made, AI-driven analysis decreases unwarranted imaging, minimizes patient burden, and streamlines resource utilization in clinical workflows.

3.3 Integration with Medical Imaging Modalities

Following biosignal processing with AI detects recurrence risk, imaging modality such as as MRI and PET are utilized to confirm or refute recurrence of the tumor. MRI is the clinical gold standard in structure and function brain imaging because of its highest spatial resolution [10, 11]. Nevertheless, distinguishing authentic recurrence from Treatment-related alterations, like radiation necrosis or pseudoprogression, persist. a challenge [6, 7]. High-content imaging is addressed through the By incorporating multiparametric MRI features with predictive modeling. Radiomics and deep learning have

dramatically enhanced the power to detect subtle

recurrence signatures in MRI scans [15, 29]. Transformer-based Advanced architectural designs and high-level segmentation frameworks, like nnU-Net, have demonstrated robustness in high-dimensional feature extraction from multimodal imaging datasets [11, 13]. These devices allow the accurate definition of the edges growth patterns, and responses to therapy. In addition, hybrid approaches that fuse PET with MRI provide metabolic complements

and anatomical insights [26]. This multimodal fusion is particularly favorable in patients with unclear MRI results, as metabolic markers obtained with PET often precede the structural changes. Along with the AI algorithms, the imaging data can be interpreted more efficiently and with greater consistency. Incorporation of bioelectronic sensor alerts with AI-based imaging platforms Ensures

those at high risk get timely appropriate imaging, while the asymptomatic ones are spared unnecessary procedures, thereby advancing precision monitoring in neuro-oncology.

3.4 Deep Learning Integration for Imaging Interpretation

Deep learning became the focal point in the exploration of brain tumor imaging, particularly in distinguishing recurrence from treatment-related changes. Once AI-based Signal analysis implies recurrence is possible; therefore, MRI or other modes of imaging are Triggered, and deep learning-based models are used to examine the scans [10, 11]. Convolution neural networks (CNNs) and transformer-based architectures have demonstrated

State-of-the-art techniques in the segmentation, detection, and classification of brain tumors tasks [4, 13]. Frameworks like nnU-Net have shown significant resilience. on medical image segmentation across multiple datasets [11]. They are especially in recurrence detection, wherein subtle changes in tumor margins or growth patterns can be troublesome to read by eye. Deep learning fueled by radiomics is also capable of extracting quantitative features

Use of MRI enhances the discrimination of recurrence from necrosis or pseudoprogression [29, 30]. Multimodal approaches those that pair PET with MRI provide more excellent diagnostic insights, and deep learning Models are progressively demonstrating the ability to utilize these integrated datasets [26]. Through standardizing and automating the imaging data interpretation with deep learning

reduces inter-observer variation and accelerates clinical decision-making. When Integrated within the holistic bioelectronic–AI system, it makes sure that imaging delivers as a reliable verification step within the continuously running monitoring pipeline.

3.5 Clinical Decision Support and Intervention

The main goal of integrating bioelectronics, artificial intelligence, and imaging methodologies is the augmentation Clinical judgement and patient outcomes in the scenario of brain tumor recurrence risk. Conventional monitoring techniques are based upon serial imaging at fixed intervals, which could prolong the detection of aggressive recurrences [6, 20]. On Utilizing continuous monitoring with biosensors Guarantees early detection of potential hazards, allowing for rapid clinical intervention.

Artificial intelligence-powered decision support systems provide healthcare professionals with risk stratification measures. and visual explanations, raising the transparency in recurrence detection [9]. Such explainability is essential in building trust in AI systems in the clinical setting Further, the application of bioelectronics as well as artificial intelligence suppresses the unnecessary scans, decreasing health care costs and reducing patient exposure to iterative imaging Methods.

From a treatment perspective, early recurrence detection improves eligibility for salvage treatments, experimental researches, and focused therapy. Additionally, these Systems remain in sync with the overriding goals of personalized medicine with tailored follow-up approaches tailored to specific patients as opposed to implementing standardized monitoring timelines [2, 3]. Most ethical concerns remain in the forefront with Preservation of the data protection is essential in the design of real-time supervision structures [16, 17].

Despite considerable progress in the development of bioelectronic sensors, artificial intelligence, and imaging modalities, further research can be done to investigate their combination with the aim of continuous monitoring of sensitive diseases as proposed in this study. Table 5 summarizes recent work combining these modalities, noting their methodologies, contributions, and clinical outcomes. This combination lies behind our suggested framework, which makes an attempt to merge implantable bioelectronics with AI-enhanced imaging analysis.

Finally, this merge of bioelectronics, AI, and imaging into oneunifu clinical process redefines how recurrence is detected and handled, opens the door for future neuro-oncology care. Figure 4 illustrates the proposed framework that integrates bioelectronic sensors, AI-driven signal analysis, medical imaging, and deep learning. This pipeline enables continuous surveillance of patients after brain tumor surgery, ensuring early detection and timely intervention in case of recurrence.

Table 5: Summary of recent research in AI, bioelectronics, or imaging and their functional contribution to diagnose brain tumor recurrence

Ref	Method / Technology	Contribution	Outcome
[1]	Developed embryonic development-mimicking soft bioelectronic mesh implants	Proposed compliant, biocompatible sensors with sustained integration capability in brain tissue	Exhibited stable long-term monitoring of neural signals with negligible immune response.
[10]	Deep learning-based classification using MRI	Established an AI model to distinguish glioblastoma recurrence from radiation necrosis	Attained high discriminatory power to differentiate recurrence from the effects of treatment.
[11]	nnU-Net architecture for biomedical segmentation	Automatic segmentation of brain tumor images from data to detect recurrence	Obtained state-of-the-art MRI dataset segmentation performance.
[12]	Neural interfacing through flexible bioelectronics	Summarized implanted and flexible devices with neural monitoring	Elucidated the importance of stretchable bioelectronics in ongoing monitoring of the brain.
[13]	Transformer-based MRI analysis	Employed brain tumor MRI recurrence analysis with developed transformer networks	Outperformed CNN-based methods in terms of precision and stability.
[15]	Multimodal fusion (imaging + genomics)	Incorporated imaging features with genomics information to yield recurrence prediction	Demonstrated through multimodal fusion to boost the prediction ability of recurrence likelihood.
[26]	PET images to track recurrence	Made use of metabolic images to distinguish tumor recurrence from postradiation changes	Improved discrimination of recurrence vs. radiation necrosis.
[27]	CSF liquid biopsy	Monitored tumor evolution over time in glioma with cerebrospinal fluid cell-free DNA	Established the promise of CSF ctDNA in tracking recurrence and early detection.




Figure 4: Proposed flowchart for continuous monitoring of brain tumor recurrence using bioelectronic sensors, AI, imaging, and deep learning.

4. Challenges

4.1 Practical Considerations

In spite of the conceptual potential, integration holds numerous challenges. Most importantly, it is critical to ensure long-implant device reliability since biocompatability and signal stability are indispensable prerequisites for clinical implementation success [12]. Moreover, there exists a severe paucity of widespread annotated datasets that bring together electrophysiology and imaging, which forms a significant barrier in AI model training. The implementation of federated learning approaches [19] can potentially mitigate the problem through multi-center collaborations while ensuring patient confidentiality.

Ethical considerations necessitate attention, especially in relation to ongoing neural observation and the privacy of data [16, 17]. Notwithstanding these obstacles, the proposed theoretical framework indicates a transformative change in post-treatment care, wherein individuals recovering from brain tumors could gain advantages from tailored, continuous monitoring systems that are proficient in the early and precise identification of recurrence.

4.2 Biocompatibility and Longevity

Soft bioelectronics minimize scarring and immune response, but long-term stability remains under investigation [1], [14].

4.3 Data Fusion

Harmonizing electrophysiological and imaging data presents significant computational and algorithmic challenges [15].

4.4 Ethical and Regulatory Considerations

Brain implants raise ethical questions about patient consent, privacy, and autonomy, particularly when used for continuous surveillance [16], [17].

5. Bridging the Gaps

Despite rapid progress, several critical gaps remain unaddressed:

- **Data Availability and Multimodality:** Presently available datasets (e.g., BraTS, TCIA) do not incorporate a synthesis of electrophysiological, biochemical, and imaging data, thereby constraining the development of genuinely multimodal artificial intelligence models [10, 11, 15].
- **Adult Biocompatibility of Bioelectronics:** The vast majority of research on stretchable implants only considered developmental or short-term animal models; long-term safety in adult human scarred tissue is still unproven [1, 12, 24].
- **Interpretability of AI Models:** Deep learning systems remain "black boxes," creating barriers to clinician trust and regulatory approval [4, 29, 30].
- **Standardization of Biomarkers:** No standard markers from neurochemical or electrophysiological measurements across all experiments constantly representing recurrence versus therapy side effects agree upon [21, 16, 17].

Filling these spaces requires interdisciplinary collaboration on research across bioelectronics, computer science, neuro-oncology, and bioethics.

6. Conclusion

Recurrence of brain tumor continues to be one of the most significant challenges in the field of neuro-oncology, most acutely for patients presenting with high-grade gliomas whose recurrence rates still remain prohibitively high despite intensive multimodal treatments [6, 7, 20]. Existing follow-up protocols, solely depending on regular MRI scan follow-ups, frequently do not capture early recurrence and thereby confine the intervention window. This paper presents the transformative promise of merging bioelectronic sensors and AI-empowered medical imaging to provide a sustained and individualised monitoring platform for the follow-up care of patients undergoing brain tumor surgery.

Bioelectronic sensors provide the distinctive ability to record electrophysiological alterations in real-time, and imaging offers structural information at high resolution. Using AI, most importantly deep-learning architectures, such data streams can be combined to improve the sensitivity and specificity in the identification of recurrence. The integration may allow clinicians to offer decision-making therapeutics earlier along the disease continuum and ultimately better long-term outcomes for patients.

However, some challenges must be overcome prior to clinical translation. These are the long-term stability and biocompatibility of implantable devices [12], the development of robust AI architectures with multimodal dataset access [4, 15], and the consequences of ongoing neural monitoring on ethics and privacy [16, 17]. It will be necessary to overcome such challenges through interdisciplinary research among biomedical engineering, computer science, and clinical oncology.

Finally, the fusion of bioelectronic sensors and imaging and artificial intelligence provides a revolutionary change in the post-operative management of brain tumors. Even if the method exists only on paper today, it promises to transform the response to tumor recurrence from reactive to proactive and reinforce the individualization, precision, and effectiveness of practices in the field of neuro-oncology.

References

[1] Y. Liu, H. Chen, J. Li *et al.*, "Brain implantation of soft bioelectronics via embryonic development," *Nature*, vol. 637, no. 8039, pp. 112–120, Jan. 2025. [Online]. Available: https://www.nature.com/articles/s41586-025-09106-8

[2] M. A. Lebedev and M. A. L. Nicolelis, "Brain–machine interfaces: past, present and future," *Trends in Neurosciences*, vol. 29, no. 9, pp. 536–546, 2006.

[3] D. A. Moses *et al.*, "Neuroprosthesis for decoding speech in a paralyzed person with anarthria," *New England Journal of Medicine*, vol. 385, no. 3, pp. 217–227, 2021.

[4] G. Litjens *et al.*, "A survey on deep learning in medical image analysis," *Medical Image Analysis*, vol. 42, pp. 60–88, 2017.

[5] K. He, X. Zhang, S. Ren, and J. Sun, "Deep residual learning for image recognition," in *Proc. IEEE CVPR*, 2016, pp. 770–778.

[6] A. Brandes *et al.*, "Recurrence patterns of glioblastoma in the era of radiochemotherapy: a clinical perspective," *J. Neurooncol.*, vol. 100, pp. 131–136, 2010.

[7] D. Reardon *et al.*, "Treatment of recurrent glioblastoma: a clinical update," *Oncologist*, vol. 19, no. 7, pp. 829–839, 2014.

[8] A. Kunii *et al.*, "EEG in patients with recurrent gliomas," *Clin. Neurophysiol.*, vol. 115, no. 11, pp. 2369–2375, 2004.

[9] R. Wennberg and J. Arruda, "EEG in brain tumor recurrence monitoring," *Neuro-Oncology Practice*, vol. 7, no. 5, pp. 547–555, 2020.

[10] S. Choudhury *et al.*, "Deep learning-based MRI classification for glioblastoma recurrence vs. radiation necrosis," *NeuroImage: Clinical*, vol. 25, 2020.

[11] A. Isensee *et al.*, "nnU-Net: Self-adapting framework for biomedical image segmentation," *Nature Methods*, vol. 18, no. 2, pp. 203–211, 2021.

[12] T. Stieglitz *et al.*, "Flexible bioelectronics for neural interfacing," *Advanced Healthcare Materials*, vol. 8, no. 9, 2019.

[13] Y. Chen *et al.*, "Transformer-based networks for brain tumor MRI analysis," *IEEE Trans. Med. Imaging*, vol. 41, no. 6, pp. 1234–1245, 2022.

[14] D. J. Chew *et al.*, "A microchannel neuroprosthesis for bladder control after spinal cord injury in rat," *Sci. Transl. Med.*, vol. 5, no. 210, 2013.

[15] Z. Xu *et al.*, "Multimodal fusion in brain tumor imaging and genomics," *Front. Oncol.*, vol. 10, 2020.

[16] J. Illes and S. Lombera, "Ethical considerations in brain–machine interfaces," *Dialogues Clin. Neurosci.*, vol. 10, no. 1, pp. 29–31, 2008.

[17] A. Yuste *et al.*, "Four ethical priorities for neurotechnologies and AI," *Nature*, vol. 551, no. 7679, pp. 159–163, 2017.

[18] C. Mead, "Neuromorphic electronic systems," *Proc. IEEE*, vol. 78, no. 10, pp. 1629–1636, 1990.

[19] Q. Yang *et al.*, "Federated learning in medical imaging," *IEEE Trans. Med. Imaging*, vol. 40, no. 12, pp. 3469–3481, 2021.

[20] Ivy Brain Tumor Center, "What are the chances a brain tumor will recur?," The Ivy Brain Tumor Center blog, 2025. [Online]. Available: `https://www.ivybraintumorcenter.org/blog/brain-tumor-recurrence/`

[21] Brandes, A.A., Franceschi, E., Tosoni, A., Blatt, V., Pession, A., Tallini, G., ... Ermani, M. (2009). Pattern of recurrence of glioblastoma after radiotherapy and concomitant temozolomide. Radiotherapy and Oncology, 91(3), 377–381.

[22] Lee, S.W., Fraass, B.A., Marsh, L.H., Herbort, K., Gebarski, S.S., Martel, M.K., ... Lawrence, T.S. (2009). Patterns of failure following high-dose radiation therapy with concomitant and adjuvant temozolomide for glioblastoma. International Journal of Radiation Oncology*Biology*Physics, 75(5), 1409–1416.

[23] Claassen, J., Taccone, F.S., Horn, P., Holtkamp, M., Stocchetti, N., Oddo, M. (2015). Recommendations on the use of EEG monitoring in critically ill patients: consensus statement from the Neurocritical Care Society. Neurocritical Care, 22(3), 423–428.

[24] Rogers, J.A., Someya, T., Huang, Y. (2020). Materials and mechanics for stretchable electronics. Advanced Materials, 32(15), 1906230.

[25] Trung, T.Q., Lee, N.E. (2021). Flexible and stretchable physical sensor integrated platforms for wearable human-activity monitoring and personal healthcare. npj Flexible Electronics, 5(1), 3.

[26] M. Galldiks, K. Law, and K. Pope, "The use of PET imaging for monitoring brain tumor recurrence," *Neuro-Oncology*, vol. 21, no. 3, pp. 343–351, 2019. [Online]. Available: `https://academic.oup.com/neuro-oncology/article/21/3/343/5146250`

[27] A. M. Miller, et al., "Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid," *Nature*, vol. 565, no. 7741, pp. 654–658, 2019. [Online]. Available: `https://www.nature.com/articles/s41586-019-0882-3`

[28] O. E. Krigolson, et al., "A portable, low-cost EEG system for real-time monitoring of brain function," *Frontiers in Human Neuroscience*, vol. 15, 2021. [Online]. Available: `https://www.frontiersin.org/articles/10.3389/fnhum.2021.730048/full`

[29] H. J. W. L. Aerts, et al., "Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach," *Nature Communications*, vol. 5, no. 4006, 2014. [Online]. Available: `https://www.nature.com/articles/ncomms5006`

[30] P. Kickingereder, et al., "Automated quantitative tumour response assessment of MRI in neuro-oncology with artificial intelligence," *The Lancet Oncology*, vol. 20, no. 5, pp. 728–740, 2019. [Online]. Available: https://www.sciencedirect.com/science/article/pii/S1470204519301603